Larry Junck

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response

Bradford A. Moffat, Thomas L. Chenevert, Theodore S. Lawrence et al. · Proceedings of the National Academy of Sciences · 2005 · 637 citations · Full text

Early Stratification, Engineering, Brain Mapping +26

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Burt Nabors, Jana Portnow, Manmeet S. Ahluwalia et al. · Journal of the National Comprehensive Cancer Network · 2020 · 538 citations · Full text

Surgical Oncology, Cancer Management, High-grade Gliomas +19

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

Patrick Y. Wen, W.K. Alfred Yung, Kathleen R. Lamborn et al. · Clinical Cancer Research · 2006 · 426 citations

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

Kathleen R. Lamborn, W.K. Alfred Yung, Susan M. Chang et al. · Neuro-Oncology · 2008 · 416 citations · Full text

Progression-free Survival, Grade Iii Gliomas, Cancer Management +17